Health and Healthcare
How Adverum Bio Is Winning With FDA Update
Published:
Last Updated:
Adverum Biotechnologies Inc. (NASDAQ: ADVM) shares made a handy gain on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA).
The FDA granted a Fast Track designation for ADVM-022, for the treatment of wet age-related macular degeneration (wAMD).
A Fast Track Designation is intended to facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill unmet medical needs. The designation enables more frequent communication with the FDA throughout a product candidate’s development and review process.
Age-related macular degeneration (AMD) is a progressive disease affecting the retinal cells in the macula, the region of the eye responsible for central vision. Disease progression results in the death of retinal cells and the gradual loss of vision. Approximately 10% of patients living with AMD have an advance form of the of the disease called wAMD, in which blood vessels begin to invade the cellular space between the layers of cells in the retina.
Leone Patterson, interim president and CEO of Adverum, commented:
The FDA’s Fast Track designation is an important recognition of our ADVM-022 gene therapy program. We look forward to working with the FDA and benefiting from the potential expedited development and regulatory path offered by their Fast Track program.
Its shares were last seen up about 4% at $6.11, with a consensus analyst price target of $10.25 and a 52-week trading range of $2.85 to $8.59.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
